September 2023 - Page 4 of 4 - BioMedWire (BMW)

FridaySep 08, 2023 10:30 am

Lucy Scientific Discovery Inc. (NASDAQ: LSDI) Is ‘One to Watch’

In July 2023, LSDI launched Twilight, a new sleep aid product The company in July 2023 announced its acquisition of SANA-013 from Wesana Health; SANA-013 is being developed for the treatment of several mental health and central nervous system conditions LSDI in May 2023 launched its new Mindful product line designed to enhance well-being and promote a mindful approach to life Also in May 2023, the company announced a partnership with non-profit TheraPsil to advance medical psilocybin access and research LSDI announced in April 2023 that its board had approved the repurchase of up to 500,000 shares of its Class…

FridaySep 08, 2023 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study

CNS Pharmaceuticals recently announced updated results from its pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin The novel anthracycline demonstrated its capability to be an innovative potential treatment option for GBM 151 patients have been enrolled in the study, marking the data cutoff point and a significant milestone toward reporting topline results before the end of the year Based on the results seen preclinically, the company remains optimistic that Berubicin may provide a much-needed clinical benefit for GBM patients CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a…

FridaySep 08, 2023 9:00 am

Longeveron Inc. (NASDAQ: LGVN) Is ‘One to Watch’

In June 2023, Longeveron filed with the SEC to offer subscription rights worth up to $30 million of shares of Class A common stock to stockholders and holders of warrants. The rights offering, which became effective on August 17, 2023, is being made through a distribution of five tradable subscription rights (listed on The NASDAQ Capital Market under the ticker symbol LGVNR) to purchase shares of Class A common stock for each share of common stock and warrant to purchase common stock owned as of the record date of August 18, 2023, at a $3.00 subscription price per share. The…

ThursdaySep 07, 2023 3:26 pm

BC Study Uncovers Cause of Four Major Pediatric Allergies

New research by scientists from the University of British Columbia (UBC) and British Columbia Children’s Hospital has revealed that four major childhood allergies may arise from a common factor. The Centers for Disease Control and Prevention (CDC) estimates that close to one in five children suffer from seasonal allergies, with 10.8% living with eczema and 5%–8% suffering from food allergies. These allergies typically occur due to factors such as outdoor and indoor triggers, irritants including perfumes and cigarette smoke, and consuming certain foods. Since each type of allergy tends to arise from different factors, developing treatment or therapy that can…

ThursdaySep 07, 2023 9:30 am

The Strategic Brilliance of Acquiring High Times IP, Including Existing Licensing Agreements and Royalty Streams in All-Stock Transaction

Lucy Scientific Beats MindMed and Seelos Therapeutics to the Punch Lucy Scientific Discovery (NASDAQ: LSDI) (“Lucy” or the “Company), a Nasdaq-listed company with holdings and operations in a variety of psychotropic businesses, just announced the acquisition of the Intellectual Property of High Times, its Licensing Agreements and Royalty Streams in all-stock transaction. This was a brilliant strategic business move. With first movers in the “Mind Science” space like MindMed (NASDAQ: MNMD) and Seelos Therapeutics (NASDAQ: SEEL) realizing than 80% and 40% year-to-date gains respectively, today’s acquisition by Lucy delivers immediate revenue, an expanded product line, a proven and highly influential…

WednesdaySep 06, 2023 9:46 am

Tracking Off-Label Cancer Treatment Could Ease Future Trials, Remedies

French researchers have discovered that tracking the use of off-label and compassionate cancer treatments could aid in the development and future use of anticancer therapies. The scientists collected data from qualifying patients aged 25 years old and younger who received cancer treatment at French pediatric cancer centers from March 2020 to June 2022. Analysis of this data allowed the research team to spot severe adverse drug reactions (ADRs) and determine how minors plus young adults responded to cancer treatments. Scientists across the globe are constantly working to develop new and innovative cancer therapies for minors as well as young adults,…

TuesdaySep 05, 2023 12:16 pm

Policies Encouraging High-Volume Facilities Disadvantage Oncology Patients in Rural Areas

A new analysis published in the “JCO Oncology Practice” journal has revealed that policies encouraging high-volume medical facilities may be harming cancer patients living in rural areas. Health policy researchers at the University of Pittsburg School of Public Health discovered that cancer patients in rural Pennsylvania counties seem to be choosing to go to lower-volume health facilities closer to their homes even when they know higher-volume facilities may provide better outcomes. Rural areas often suffer from shortages of critical skills as most skilled professionals opt to move to urban areas for better pay. Rural America has a major shortage of…

TuesdaySep 05, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline

U.S.-based gene therapy developer Genprex, Inc. is developing new therapies for fighting cancer tumors and diabetes The company’s gene therapies for battling types 1 and 2 diabetes use a simple endoscopic procedure to introduce select insulin-boosting genes directly to the pancreas to combat insulin decline factors in the body The company is working with research collaborators at the University of Pittsburgh (Pitt) and recently announced a new license agreement in relation to a gene therapy for both Type 1 and Type 2 diabetes The company’s novel infusion process using related gene therapy has shown statistically significant results in preclinical testing…

FridaySep 01, 2023 1:05 pm

Bloomreach Unveils Conversational AI Tool for Online Shoppers

Marketing automation and software company Bloomreach has unveiled a conversational artificial intelligence (AI) tool to help online shoppers as they navigate e-commerce stores. Called Bloomreach Clarity, the new AI tool is powered by large language models and generative AI, a type of AI with the ability to produce all types of content including texts, images and video. The tool will help virtual stores provide human-like and personalized product information from their favorite companies and brands. It will also allow businesses to connect conversations with the AI model to specific product catalogs and integrate conversations from different communication channels. Machine learning…